Nothing Special   »   [go: up one dir, main page]

RU2337692C3 - Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 - Google Patents

Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3

Info

Publication number
RU2337692C3
RU2337692C3 RU2004116472A RU2004116472A RU2337692C3 RU 2337692 C3 RU2337692 C3 RU 2337692C3 RU 2004116472 A RU2004116472 A RU 2004116472A RU 2004116472 A RU2004116472 A RU 2004116472A RU 2337692 C3 RU2337692 C3 RU 2337692C3
Authority
RU
Russia
Prior art keywords
tyrosine kinase
receptor tyrosine
kinase activity
flt3 receptor
inhibitors
Prior art date
Application number
RU2004116472A
Other languages
English (en)
Other versions
RU2337692C2 (ru
RU2004116472A (ru
Original Assignee
Новартис Аг
Дана-Фарбер Кэнсер Инститьют Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2337692(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг, Дана-Фарбер Кэнсер Инститьют Инк. filed Critical Новартис Аг
Publication of RU2004116472A publication Critical patent/RU2004116472A/ru
Publication of RU2337692C2 publication Critical patent/RU2337692C2/ru
Application granted granted Critical
Publication of RU2337692C3 publication Critical patent/RU2337692C3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

1. Применение N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамида формулы (VII)
Figure 00000001
для получения фармацевтической композиции, предназначенной для лечения заболевания, связанного с неконтролируемой активностью рецепторной тирозинкиназы FLT3, которое представляет собой острый миелолейкоз.
2. Фармацевтический препарат для лечения лейкоза, включающий N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамид формулы (VII) в эффективном количестве.
RU2004116472A 2001-10-30 2002-10-29 Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 RU2337692C3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33903101P 2001-10-30 2001-10-30
US60/339,031 2001-10-30
US33818501P 2001-12-07 2001-12-07
US60/338,185 2001-12-07

Publications (3)

Publication Number Publication Date
RU2004116472A RU2004116472A (ru) 2005-05-10
RU2337692C2 RU2337692C2 (ru) 2008-11-10
RU2337692C3 true RU2337692C3 (ru) 2020-11-09

Family

ID=26991080

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004116472A RU2337692C3 (ru) 2001-10-30 2002-10-29 Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3

Country Status (26)

Country Link
US (3) US7973031B2 (ru)
EP (1) EP1441737B1 (ru)
JP (1) JP4959918B2 (ru)
KR (2) KR100926194B1 (ru)
CN (2) CN101703509A (ru)
AT (1) ATE335490T1 (ru)
AU (1) AU2006249245B2 (ru)
BR (1) BRPI0213739B8 (ru)
CA (1) CA2462657C (ru)
CY (1) CY1106199T1 (ru)
DE (1) DE60213842T2 (ru)
DK (1) DK1441737T3 (ru)
ES (1) ES2269793T3 (ru)
FR (1) FR18C1012I2 (ru)
HK (1) HK1068262A1 (ru)
HU (1) HU230798B1 (ru)
IL (2) IL161156A0 (ru)
MX (1) MXPA04004137A (ru)
NO (1) NO335685B1 (ru)
NZ (1) NZ532136A (ru)
PL (1) PL211461B1 (ru)
PT (1) PT1441737E (ru)
RU (1) RU2337692C3 (ru)
TW (1) TWI302836B (ru)
WO (1) WO2003037347A1 (ru)
ZA (1) ZA200402498B (ru)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005011598A2 (en) * 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
EP2305265A1 (en) * 2003-08-08 2011-04-06 Novartis AG Combinations comprising staurosporines
US20080221080A1 (en) * 2003-08-25 2008-09-11 James Douglas Griffin Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
WO2005053704A1 (en) * 2003-12-01 2005-06-16 Novartis Ag Method for predicting drug responsiveness in myeloid neoplasms
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス, インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
CN103251953A (zh) * 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN101106983A (zh) * 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
GB0426821D0 (en) * 2004-12-07 2005-01-12 Novartis Ag Organic compounds
CN103130735B (zh) 2005-05-10 2016-08-03 因塞特控股公司 吲哚胺2,3-双加氧酶调节剂及其用法
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007010013A2 (en) * 2005-07-20 2007-01-25 Novartis Ag Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
JP2009511628A (ja) 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Flt3キナーゼの阻害方法
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
US7973032B2 (en) 2005-11-14 2011-07-05 University Of Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
KR101406877B1 (ko) 2006-04-20 2014-06-13 얀센 파마슈티카 엔.브이. C-fms 키나제의 저해제
US7414050B2 (en) 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
UA104849C2 (ru) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины как ингибиторы киназ janus
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
HUE036813T2 (hu) 2008-07-08 2018-07-30 Incyte Holdings Corp 1,2,5-Oxadiazolok mint indolamin-2,3-dioxigenáz inhibitorok
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2448938E (pt) 2009-06-29 2014-07-31 Incyte Corp Pirimidinonas como inibidoras de pi3k
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2486041E (pt) 2009-10-09 2013-11-14 Incyte Corp Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011086085A1 (en) 2010-01-12 2011-07-21 Ab Science Thiazole and oxazole kinase inhibitors
CA2790070C (en) 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションIncyte Corporation PI3Kδ阻害剤としての縮合誘導体
KR102040479B1 (ko) 2010-05-21 2019-11-06 인사이트 홀딩스 코포레이션 Jak 저해제에 대한 국소 제형
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
JP2014521725A (ja) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト JAKPI3K/mTOR併用療法
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
DK3513793T3 (da) 2011-09-02 2021-04-26 Incyte Holdings Corp Heterocyclylaminer som pi3k-inhibitorer
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX368315B (es) * 2012-04-24 2019-09-27 Int Stem Cell Corporation Derivación de células madre neurales y neuronas dopaminérgicas a partir de células madre pluripotentes humanas.
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
AR091424A1 (es) 2012-06-13 2015-02-04 Incyte Corp Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
SG11201503141TA (en) 2012-11-01 2015-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
IL291391B (en) 2012-11-15 2022-11-01 Incyte Holdings Corp Sustained release dosage forms of roxolitinib
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
EP2964650B1 (en) 2013-03-06 2018-12-05 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3786162B1 (en) 2013-05-17 2023-08-09 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US10463658B2 (en) * 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS57723B1 (sr) 2014-02-28 2018-12-31 Incyte Corp Jak1 inhibitori za lečenje mijelodisplastičnog sindroma
PL3116909T3 (pl) 2014-03-14 2020-05-18 Novartis Ag Cząsteczki przeciwciał przeciw LAG-3 i ich zastosowanie
MY185686A (en) 2014-04-08 2021-05-30 Incyte Corp Treatment of b-cell malignancies by a combination jak and p13k inhibitor
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
EP3268035A4 (en) 2015-03-10 2018-10-31 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
CN106083830B (zh) * 2016-06-01 2019-07-12 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3359155A4 (en) 2016-11-02 2019-05-22 Arog Pharmaceuticals, Inc. CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107417743B (zh) * 2017-06-15 2020-07-21 杭州科兴生物化工有限公司 星孢菌素醛基取代衍生物及其制备方法和应用
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
IL276302B2 (en) 2018-01-30 2023-11-01 Incyte Corp Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
JP2021513981A (ja) 2018-02-16 2021-06-03 インサイト・コーポレイションIncyte Corporation サイトカイン関連障害を治療するためのjak1経路阻害薬
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
TW202413336A (zh) 2018-03-08 2024-04-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピリミジン誘導体
CA3101368A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
UA128332C2 (uk) 2018-07-05 2024-06-12 Інсайт Корпорейшн Похідні конденсованих піразинів як інгібітори a2a/a2b
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
MA53561A (fr) 2018-09-05 2022-05-11 Incyte Corp Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP2022515705A (ja) 2018-11-01 2022-02-22 サイロス ファーマシューティカルズ, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
CA3130210A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP7532511B2 (ja) 2019-06-10 2024-08-13 インサイト・コーポレイション Jak阻害剤による尋常性白斑の局所治療
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ido阻害剤の投与レジメン
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
EP4021907A1 (en) 2019-08-26 2022-07-06 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
US11839619B2 (en) 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4041731A1 (en) 2019-10-11 2022-08-17 Incyte Corporation Bicyclic amines as cdk2 inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
MX2022012780A (es) 2020-04-16 2023-01-18 Incyte Corp Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2021247668A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
CN116261447A (zh) 2020-09-16 2023-06-13 因赛特公司 局部治疗白癜风
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
EP4370515A1 (en) 2021-07-14 2024-05-22 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EP4436578A1 (en) 2021-11-22 2024-10-02 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TW202340215A (zh) 2021-12-22 2023-10-16 美商英塞特公司 Fgfr抑制劑之鹽及固體形式以及其製備方法
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Cdk2抑制劑及其用途
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
AR128717A1 (es) 2022-03-07 2024-06-05 Incyte Corp Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
CN114853784B (zh) * 2022-06-16 2023-09-05 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱类化合物及其制备方法与应用
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
TW202419088A (zh) 2022-08-05 2024-05-16 美商英塞特公司 使用jak抑制劑之蕁麻疹治療
WO2024220645A1 (en) 2023-04-18 2024-10-24 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
WO1989007105A1 (en) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
WO1991009034A1 (en) * 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5658895A (en) * 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
EP0651752A1 (en) 1992-07-20 1995-05-10 Behringwerke Ag Novel chemiluminescent compounds and methods of use
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP0763042A1 (en) 1994-06-01 1997-03-19 Novartis AG Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
JPH09299092A (ja) * 1996-03-12 1997-11-25 Takeda Chem Ind Ltd 新規タンパク質およびそのdna
AU4205597A (en) 1996-08-20 1998-03-06 Novartis Ag Methods for prevention of cellular proliferation and restenosis
RO120603B1 (ro) 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
JP2001523707A (ja) 1997-11-26 2001-11-27 イーライ・リリー・アンド・カンパニー 慢性骨髄性白血病および急性リンパ性白血病のための治療的処置
DE69940158D1 (de) 1998-08-20 2009-02-05 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von potenziellen verbindungen für das auffinden von einem anti-tumor-arzneistoff
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1068262A1 (en) 2005-04-29
CA2462657C (en) 2011-04-26
ATE335490T1 (de) 2006-09-15
US8222244B2 (en) 2012-07-17
FR18C1012I1 (fr) 2018-04-27
BRPI0213739B8 (pt) 2021-05-25
PT1441737E (pt) 2006-12-29
KR20050040842A (ko) 2005-05-03
KR100926194B1 (ko) 2009-11-09
KR20090087139A (ko) 2009-08-14
IL161156A0 (en) 2004-08-31
DE60213842D1 (de) 2006-09-21
ES2269793T3 (es) 2007-04-01
TWI302836B (en) 2008-11-11
BRPI0213739B1 (pt) 2020-06-09
ZA200402498B (en) 2005-07-27
IL161156A (en) 2011-02-28
EP1441737A1 (en) 2004-08-04
NO335685B1 (no) 2015-01-19
EP1441737B1 (en) 2006-08-09
AU2006249245B2 (en) 2009-11-05
US8445479B2 (en) 2013-05-21
MXPA04004137A (es) 2005-01-25
JP2005507412A (ja) 2005-03-17
US20120252785A1 (en) 2012-10-04
AU2006249245A1 (en) 2007-01-04
HUP0401642A2 (hu) 2004-11-29
BR0213739A (pt) 2004-10-19
PL368322A1 (en) 2005-03-21
DE60213842T2 (de) 2007-09-06
TW200301127A (en) 2003-07-01
HUP0401642A3 (en) 2008-05-28
CA2462657A1 (en) 2003-05-08
CN101703509A (zh) 2010-05-12
CN1582150B (zh) 2011-09-07
CY1106199T1 (el) 2011-06-08
JP4959918B2 (ja) 2012-06-27
RU2337692C2 (ru) 2008-11-10
RU2004116472A (ru) 2005-05-10
HU230798B1 (hu) 2018-06-28
FR18C1012I2 (fr) 2021-06-11
NZ532136A (en) 2006-08-31
US7973031B2 (en) 2011-07-05
WO2003037347A1 (en) 2003-05-08
CN1582150A (zh) 2005-02-16
US20110224194A1 (en) 2011-09-15
PL211461B1 (pl) 2012-05-31
US20050020570A1 (en) 2005-01-27
DK1441737T3 (da) 2006-11-13
NO20042123L (no) 2004-07-13

Similar Documents

Publication Publication Date Title
RU2337692C3 (ru) Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
DK1020179T3 (da) Peptidderivater eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling af de samme, anvendelse af derivaterne og farmaceutisk sammensætning
ME00513B (me) Azabicikloalkani kao modulatori ccr5
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
HUP0102300A3 (en) Use of diazepin derivatives for preparing medicines for treating diseases influenced by somatostatine receptor, and new compounds
DE59708771D1 (de) Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo- 4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
EE05242B1 (et) 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
DE60001586D1 (de) Diphenyl-piperidin derivate
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
HUP0100012A2 (hu) Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére
FR2718451B1 (fr) Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.
MX9805088A (es) Derivados de octahidro-pirrolo[1,2-a]-pirazina 2,7-sustituidos.
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
WO2001007418A3 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
FR2788776B1 (fr) Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2793247B1 (fr) Derives de 6-[[(aryl et heteroaryl)oxy]methyl]naphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
FR2833953B1 (fr) DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
NO20001895D0 (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
ES2186639T3 (es) Nuevos derivados de ((2-sustituido-5-(3-tienil))-bencil)-(2-((2-isopropoxi-5-fluoro)-fenoxi)-etil)-amina, su procedimiento de preparacion y su utilizacion como medicamentos.
BR9807701A (pt) Derivados de 4-aminoalcóxi-1h-benzimidazol, seu preparo e seu uso como agonistas do auto-receptor (d2) de dopamina
FR2790472B1 (fr) Derives de cyclobutene-3, 4-dione, leur preparation et leur application en therapeutique
ES2185985T3 (es) Derivados de 4-aminoetoxiindolona como agonistas del receptor d2 de dopamina.
KR950703572A (ko) A-2 수용체 친화성을 갖는 2-치환된 아데노신[2-Substituted adenosines with A-2receptor affinity]
IT1261994B (it) Derivati guanidinici ad uso terapeutico.

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20201109